UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(Mark One) | | | | | |
☑ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended March 31, 2024
OR | | | | | |
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number: 001-15169
PERFICIENT, INC.
(Exact name of registrant as specified in its charter) | | | | | | | | | | | | | | |
Delaware | | No. | 74-2853258 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
555 Maryville University Drive
Suite 600
Saint Louis, Missouri 63141
(Address of principal executive offices)
(314) 529-3600
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act: | | | | | | | | |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Common Stock, $0.001 par value | PRFT | The Nasdaq Global Select Market |
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements during the past 90 days. þ Yes o No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). þ Yes o No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | | | | | | | | | |
Large accelerated filer | þ | Accelerated filer | ☐ |
Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
Emerging growth company | ☐ | | |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No þ
As of April 25, 2024, there were 35,156,319 shares of Common Stock outstanding.
TABLE OF CONTENTS
PART I. FINANCIAL INFORMATION
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Certain statements contained in this Quarterly Report on this Form 10-Q (“Form 10-Q”) are not purely historical statements, discuss future expectations, contain projections of results of operations or financial condition, or state other forward-looking information. Those statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those contemplated by the statements. The “forward-looking” information is based on various factors and was derived using numerous assumptions. In some cases, you can identify these so-called forward-looking statements by words like “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of those words and other comparable words. You should be aware that those statements only reflect our predictions and are subject to risks and uncertainties. Actual events or results may differ substantially. Important factors that could cause our actual results to be materially different from the forward-looking statements include (but are not limited to) the following:
(1)the impact of the general economy and economic and political uncertainty on our business;
(2)risks associated with potential changes to U.S. and foreign laws, regulations, and policies;
(3)risks associated with the operation of our business generally, including:
a. client demand for our services and solutions;
b. effectively competing in a highly competitive market;
c. risks from international operations including fluctuations in exchange rates;
d. adapting to changes in technologies and offerings;
e. the ongoing transition of our executive leadership team;
f. obtaining favorable pricing to reflect services provided;
g. risk of loss of one or more significant software vendors;
h. maintaining a balance of our supply of skills and resources with client demand;
i. changes to immigration policies;
j. protecting our clients’ and our data and information;
k. changes to tax levels, audits, investigations, tax laws or their interpretation;
l. making appropriate estimates and assumptions in connection with preparing our consolidated financial statements; and
m. maintaining effective internal controls;
(4)risks associated with managing growth organically and through acquisitions;
(5)risks associated with servicing our debt, the potential impact on the value of our common stock from the conditional conversion features of our debt and the associated convertible note hedge transactions;
(6)legal liabilities, including intellectual property protection and infringement or the disclosure of personally identifiable information;
(7)the risks detailed from time to time within our filings with the Securities and Exchange Commission (the “SEC”);
(8)uncertainties associated with the proposed merger of Perficient with an affiliate of BPEA Private Equity Fund VIII (“EQT Asia”);
(9)the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement entered into in connection with the proposed merger;
(10)risks related to disruption of management time from ongoing business operations due to the proposed merger;
(11)the risk that the conditions to the proposed merger may not be satisfied in a timely manner or at all;
(12)the risk of any unexpected costs or expenses resulting from the proposed merger;
(13)restrictions imposed on our business during the pendency of the proposed merger;
(14)the risk of any litigation relating to the proposed merger; and
(15)the risk that the proposed merger and its announcement could have an adverse effect on the ability of Perficient to retain and hire key personnel and to maintain relationships with customers, vendors, partners, employees, stockholders and other business relationships and on its operating results and business generally.
This discussion is not exhaustive, but is designed to highlight important factors that may impact our forward-looking statements. Because the factors referred to above, as well as the statements included under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, including documents incorporated by reference therein and herein, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statement made by us or on our behalf, you should not place undue reliance on any forward-looking statements.
Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. We are under no duty to update any of the forward-looking statements after the date of this Form 10-Q to conform such statements to actual results.
All forward-looking statements, express or implied, included in this report and the documents we incorporate by reference that are attributable to Perficient, Inc. and its subsidiaries (collectively, “we,” “us,” “Perficient,” or the “Company”) are expressly qualified in their entirety by this cautionary statement. This cautionary statement should also be considered in connection with any subsequent written or oral forward-looking statements that the Company or any persons acting on our behalf may issue.
Item 1. Financial Statements
Perficient, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share information)
| | | | | | | | | | | |
| March 31, 2024 (unaudited) | | December 31, 2023 |
Assets | |
Current assets: | | | |
Cash, cash equivalents and restricted cash | $ | 118,193 | | | $ | 128,886 | |
Accounts receivable, net | 171,838 | | | 178,998 | |
Prepaid expenses | 5,758 | | | 5,638 | |
Other current assets | 13,548 | | | 12,431 | |
Total current assets | 309,337 | | | 325,953 | |
Property and equipment, net | 10,375 | | | 11,996 | |
Operating lease right-of-use assets | 22,812 | | | 21,786 | |
Goodwill | 613,790 | | | 581,387 | |
Intangible assets, net | 75,430 | | | 71,118 | |
Other non-current assets | 53,936 | | | 52,364 | |
Total assets | $ | 1,085,680 | | | $ | 1,064,604 | |
| | | |
Liabilities and Stockholders’ Equity | | | |
Current liabilities: | | | |
Accounts payable | $ | 13,919 | | | $ | 18,688 | |
Other current liabilities | 60,104 | | | 59,784 | |
Total current liabilities | 74,023 | | | 78,472 | |
Long-term debt, net | 397,446 | | | 396,874 | |
Operating lease liabilities | 17,915 | | | 16,446 | |
Other non-current liabilities | 42,566 | | | 42,189 | |
Total liabilities | $ | 531,950 | | | $ | 533,981 | |
Stockholders’ equity: | | | |
Preferred stock (par value $0.001 per share; 8,000,000 authorized; no shares issued or outstanding as of March 31, 2024 and December 31, 2023) | $ | — | | | $ | — | |
Common stock (par value $0.001 per share; 100,000,000 authorized; 53,833,315 shares issued and 34,455,848 shares outstanding as of March 31, 2024; 53,465,127 shares issued and 34,174,200 shares outstanding as of December 31, 2023) | 54 | | | 53 | |
Additional paid-in capital | 448,855 | | | 432,160 | |
Accumulated other comprehensive loss | (6,336) | | | (5,461) | |
Treasury stock, at cost (19,377,467 shares as of March 31, 2024; 19,290,927 shares as of December 31, 2023) | (377,594) | | | (373,325) | |
Retained earnings | 488,751 | | | 477,196 | |
Total stockholders’ equity | 553,730 | | | 530,623 | |
Total liabilities and stockholders’ equity | $ | 1,085,680 | | | $ | 1,064,604 | |
See accompanying notes to interim unaudited condensed consolidated financial statements.
Perficient, Inc.
Unaudited Condensed Consolidated Statements of Operations
(in thousands, except per share information)
| | | | | | | | | | | | | | | |
| Three Months Ended | | |
| March 31, | | |
| 2024 | | 2023 | | | | |
| | | | | | | |
Revenues | $ | 215,304 | | | $ | 231,408 | | | | | |
| | | | | | | |
| | | | | | | |
Cost of revenues (exclusive of depreciation and amortization, shown separately below) | | | | | | | |
Cost of services | 139,599 | | | 141,688 | | | | | |
Stock compensation | 2,507 | | | 2,524 | | | | | |
Total cost of revenues | 142,106 | | | 144,212 | | | | | |
| | | | | | | |
Selling, general and administrative | 39,243 | | | 39,604 | | | | | |
Stock compensation | 9,923 | | | 4,316 | | | | | |
Total selling, general and administrative | 49,166 | | | 43,920 | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
Depreciation | 2,011 | | | 2,305 | | | | | |
Amortization | 4,886 | | | 5,817 | | | | | |
Acquisition costs | 1,393 | | | 79 | | | | | |
Adjustment to fair value of contingent consideration | 41 | | | (2,026) | | | | | |
Income from operations | 15,701 | | | 37,101 | | | | | |
| | | | | | | |
Net interest (income) expense | (767) | | | 505 | | | | | |
| | | | | | | |
Net other (income) expense | (45) | | | 75 | | | | | |
Income before income taxes | 16,513 | | | 36,521 | | | | | |
Provision for income taxes | 4,958 | | | 9,721 | | | | | |
| | | | | | | |
Net income | $ | 11,555 | | | $ | 26,800 | | | | | |
| | | | | | | |
Basic net income per share | $ | 0.34 | | | $ | 0.79 | | | | | |
Diluted net income per share | $ | 0.33 | | | $ | 0.75 | | | | | |
Shares used in computing basic net income per share | 34,149 | | | 33,914 | | | | | |
Shares used in computing diluted net income per share | 36,905 | | | 36,697 | | | | | |
See accompanying notes to interim unaudited condensed consolidated financial statements.
Perficient, Inc.
Unaudited Condensed Consolidated Statements of Comprehensive Income
(in thousands)
| | | | | | | | | | | | | | | |
| Three Months Ended | | |
| March 31, | | |
| 2024 | | 2023 | | | | |
| | | |
Net income | $ | 11,555 | | | $ | 26,800 | | | | | |
Other comprehensive (loss) income: | | | | | | | |
| | | | | | | |
Foreign currency translation adjustment, net of tax | (875) | | | 1,772 | | | | | |
Comprehensive income | $ | 10,680 | | | $ | 28,572 | | | | | |
See accompanying notes to interim unaudited condensed consolidated financial statements.
Perficient, Inc.
Unaudited Condensed Consolidated Statements of Stockholders’ Equity
(in thousands) | | | | | | | | | | | | | | | | | | |
| | Three Months Ended | | |
| | March 31, | | |
| | 2024 | | 2023 | | | | |
| | | | | | | |
| | | | | | | |
Common Stock | | | | | | | |
Beginning of period | $ | 53 | | | $ | 53 | | | | | |
| Stock compensation related to restricted stock vesting and retirement savings plan contributions | 1 | | | — | | | | | |
End of period | 54 | | | 53 | | | | | |
Additional Paid-in Capital | | | | | | | |
Beginning of period | 432,160 | | | 403,866 | | | | | |
| Proceeds from the sales of stock through the Employee Stock Purchase Plan | 197 | | | 240 | | | | | |
| Stock compensation related to restricted stock vesting and retirement savings plan contributions | 12,506 | | | 6,853 | | | | | |
| Issuance of stock in conjunction with acquisition including stock attributed to future compensation | 3,992 | | | — | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
End of period | 448,855 | | | 410,959 | | | | | |
Accumulated Other Comprehensive Loss | | | | | | | |
Beginning of period | (5,461) | | | (17,519) | | | | | |
| | | | | | | | |
| Foreign currency translation adjustment | (875) | | | 1,772 | | | | | |
End of period | (6,336) | | | (15,747) | | | | | |
Treasury Stock | | | | | | | |
Beginning of period | (373,325) | | | (354,536) | | | | | |
| Purchases of treasury stock and buyback of shares for taxes | (4,269) | | | (7,449) | | | | | |
| | | | | | | | |
| Stock reacquired for escrow claim | — | | | (164) | | | | | |
End of period | (377,594) | | | (362,149) | | | | | |
Retained Earnings | | | | | | | |
Beginning of period | 477,196 | | | 378,263 | | | | | |
| | | | | | | | |
| Net income | 11,555 | | | 26,800 | | | | | |
End of period | 488,751 | | | 405,063 | | | | | |
Total Stockholders’ Equity | $ | 553,730 | | | $ | 438,179 | | | | | |
| | | | | | | | | | | | | | | | | | |
| | | | |
| | | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | |
| | | | | | | |
| | Three Months Ended | | |
| | March 31, | | |
Common Stock, shares | 2024 | | 2023 | | | | |
Beginning of period | 34,174 | | | 34,072 | | | | | |
| Sales of stock through the Employee Stock Purchase Plan | 3 | | | 4 | | | | | |
| Stock compensation related to restricted stock vesting, retirement savings plan contributions and other | 298 | | | 191 | | | | | |
| Purchases of treasury stock, buyback of shares for taxes and other | (87) | | | (106) | | | | | |
| Issuance of stock in conjunction with acquisition including stock attributed to future compensation | 68 | | | — | | | | | |
| Stock reacquired for escrow claim | — | | | (2) | | | | | |
End of period | 34,456 | | | 34,159 | | | | | |
See accompanying notes to interim unaudited condensed consolidated financial statements.
Perficient, Inc.
Unaudited Condensed Consolidated Statements of Cash Flows
(in thousands) | | | | | | | | | | | |
| Three Months Ended March 31, |
| 2024 | | 2023 |
Operating Activities | |
Net income | $ | 11,555 | | | $ | 26,800 | |
Adjustments to reconcile net income to net cash provided by operations: | | | |
Depreciation | 2,011 | | | 2,305 | |
Amortization | 4,886 | | | 5,817 | |
| | | |
Deferred income taxes | (796) | | | (1,885) | |
Non-cash stock compensation and retirement savings plan contributions | 12,222 | | | 6,674 | |
Amortization of debt issuance costs | 631 | | | 608 | |
Adjustment to fair value of contingent consideration for purchase of businesses | 41 | | | (2,026) | |
| | | |
Changes in operating assets and liabilities, net of business acquisitions: | | | |
Accounts receivable | 10,928 | | | 18,784 | |
Other assets | (1,360) | | | 5,705 | |
Accounts payable | (4,824) | | | (9,909) | |
Other liabilities | (3,323) | | | (11,542) | |
Net cash provided by operating activities | 31,971 | | | 41,331 | |
| | | |
Investing Activities | | | |
Purchase of property and equipment | (319) | | | (1,015) | |
Capitalization of internally developed software costs | (341) | | | (328) | |
Purchase of businesses, net of cash acquired | (33,157) | | | 28 | |
Net cash used in investing activities | (33,817) | | | (1,315) | |
| | | |
Financing Activities | | | |
| | | |
| | | |
| | | |
Payment for credit facility financing fees | — | | | (683) | |
| | | |
| | | |
Payment of contingent consideration for purchase of business | (4,516) | | | (21,530) | |
Proceeds from the sale of stock through the Employee Stock Purchase Plan | 197 | | | 240 | |
Purchases of treasury stock | — | | | (2,395) | |
Remittance of taxes withheld as part of a net share settlement of restricted stock vesting | (4,269) | | | (5,054) | |
Net cash used in financing activities | (8,588) | | | (29,422) | |
Effect of exchange rate on cash, cash equivalents and restricted cash | (259) | | | 271 | |
Change in cash, cash equivalents and restricted cash | (10,693) | | | 10,865 | |
Cash, cash equivalents and restricted cash at beginning of period | 128,886 | | | 30,130 | |
Cash, cash equivalents and restricted cash at end of period | $ | 118,193 | | | $ | 40,995 | |
See accompanying notes to interim unaudited condensed consolidated financial statements.
| | | | | | | | | | | |
| Three Months Ended March 31, |
| 2024 | | 2023 |
Supplemental Disclosures: | | | |
Cash paid for income taxes | $ | 2,770 | | | $ | 1,553 | |
Cash paid for interest | $ | 278 | | | $ | 136 | |
| | | |
Non-Cash Investing Activity: | | | |
Stock issued for purchase of businesses (stock reacquired for escrow claim) | $ | 3,809 | | | $ | (164) | |
See accompanying notes to interim unaudited condensed consolidated financial statements.
PERFICIENT, INC.
NOTES TO INTERIM UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
MARCH 31, 2024
1. Basis of Presentation
The accompanying interim unaudited condensed consolidated financial statements of Perficient, Inc. and its subsidiaries (collectively, the “Company”) have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and are presented in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) applicable to interim financial information. Accordingly, certain note disclosures have been condensed or omitted. In the opinion of management, the interim unaudited condensed consolidated financial statements reflect all adjustments (consisting of only normal recurring adjustments) necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the periods presented. These financial statements should be read in conjunction with the Company’s consolidated financial statements and notes thereto filed with the SEC in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. Certain reclassifications were made to prior year amounts to conform to the 2024 presentation.
2. Summary of Significant Accounting Policies
Use of Estimates
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates, and such differences could be material to the financial statements.
There have been no changes to significant accounting policies described in the Annual Report on Form 10-K for the year ended December 31, 2023 that have had a material impact on the Company’s condensed consolidated financial statements and related notes.
3. Recent Accounting Pronouncements
In November 2023, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2023-07, Segment Reporting (Topic 280) Improvements To Reportable Segment Disclosures, which requires additional disclosures about a public entity’s reportable segments and addresses requests from investors and other allocators of capital for additional, more detailed information about a reportable segment’s expenses. The Company will adopt this ASU retrospectively for the annual period beginning on January 1, 2024 and for interim periods beginning on January 1, 2025.
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740) Improvements To Income Tax Disclosures, which requires additional disclosures of income tax components that affect the rate reconciliation and income taxes paid, broken out by the applicable taxing jurisdictions. The Company expects to adopt this ASU prospectively for the annual period beginning on January 1, 2025.
4. Revenue
The Company’s revenues consist of services and software and hardware sales. In accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers, revenues are recognized when control of services or goods are transferred to clients, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those services or goods.
Services Revenues
Services revenues are primarily comprised of professional services that include developing, implementing, automating and extending business processes, technology infrastructure, and software applications. The Company’s professional services span multiple industries, platforms and solutions; however, the Company has remained relatively diversified and does not believe that it has significant revenue concentration within any single industry, platform or solution.
Professional services revenues are recognized over time as services are rendered. Most projects are performed on a time and materials basis, while a portion of revenues is derived from projects performed on a fixed fee or fixed fee percent complete basis. For time and material contracts, revenues are generally recognized and invoiced by multiplying the number of hours expended in the performance of the contract by the hourly rates. For fixed fee contracts, revenues are generally recognized and invoiced by multiplying the fixed rate per time period established in the contract by the number of time periods elapsed. For fixed fee percent complete contracts, revenues are generally recognized using an input method based on the ratio of hours expended to total estimated hours, and the client is invoiced according to the agreed-upon schedule detailing the amount and timing of payments in the contract.
Clients are typically billed monthly for services provided during that month but can be billed on a more or less frequent basis as determined by the contract. If the time is worked and approved at the end of a fiscal period and the invoice has not yet been sent to the client, the amount is recorded as revenue once the Company verifies all other revenue recognition criteria have been met, and the amount is classified as a receivable as the right to consideration is unconditional at that point. Amounts invoiced in excess of revenues recognized are contract liabilities, which are classified as deferred revenues in the Unaudited Condensed Consolidated Balance Sheet. The term between invoicing and payment due date is not significant. Contracts for professional services provide for a general right, to the client or the Company, to cancel or terminate the contract within a given period of time (generally 10 to 30 days’ notice is required). The client is responsible for any time and expenses incurred up to the date of cancellation or termination of the contract. Certain contracts may include volume discounts or holdbacks, which are accounted for as variable consideration, but are not typically significant. The Company estimates variable consideration based on historical experience and forecasted sales and includes the variable consideration in the transaction price.
Other services revenues are comprised of hosting fees, partner referral fees, maintenance agreements, training and internally developed software-as-a-service (“SaaS”) sales. Revenues from hosting fees, maintenance agreements, training and internally developed SaaS sales are generally recognized over time using a time-based measure of progress as services are rendered. Partner referral fees are recorded at a point in time upon meeting specified requirements to earn the respective fee.
On many professional service projects, the Company is also reimbursed for out-of-pocket expenses including travel and other project-related expenses. These reimbursements are included as a component of the transaction price of the respective professional services contract and are invoiced as the expenses are incurred. The Company structures its professional services arrangements to recover the cost of reimbursable expenses without a markup.
Software and Hardware Revenues
Software and hardware revenues are comprised of third-party software and hardware resales, in which the Company is considered the agent, and sales of internally developed software, in which the Company is considered the principal. Third-party software and hardware revenues are recognized and invoiced when the Company fulfills its obligation to arrange the sale, which occurs when the purchase order with the vendor is executed and the customer has access to the software or the hardware has been shipped to the customer. Internally developed software revenues are recognized and invoiced when control is transferred to the customer, which occurs when the software has been made available to the customer and the license term has commenced. Revenues from third-party software and hardware sales are recorded on a net basis, while revenues from internally developed software sales are recorded on a gross basis. There are no significant cancellation or termination-type provisions for the Company’s software and hardware sales, and the term between invoicing and payment due date is not significant.
Revenues are presented net of taxes assessed by governmental authorities. Sales taxes are generally collected and subsequently remitted on all software and hardware sales and certain services transactions as appropriate.
Arrangements with Multiple Performance Obligations
Arrangements with clients may contain multiple promises such as delivery of software, hardware, professional services or post-contract support services. These promises are accounted for as separate performance obligations if they are distinct. For arrangements with clients that contain multiple performance obligations, the transaction price is allocated to the separate performance obligations based on estimated relative standalone selling price, which is estimated by the expected cost plus a margin approach, taking into consideration market conditions and competitive factors. Because contracts that contain multiple performance obligations are typically short term due to the contract cancellation provisions, the allocation of the transaction price to the separate performance obligations is not considered a significant estimate.
Contract Costs
In accordance with the terms of the Company’s sales commission plan, commissions are not earned until the related revenue is recognized. Therefore, sales commissions are expensed as they are earned. Certain sales incentives are accrued based on achievement of specified bookings goals. For these incentives, the Company applies the practical expedient that allows the Company to expense the incentives as incurred because the amortization period would have been one year or less.
Deferred Revenue
The Company’s deferred revenue balance as of March 31, 2024 and December 31, 2023 was $3.3 million and $5.5 million, respectively. Substantially all of the December 31, 2023 deferred revenue balance was recognized in revenue during the three months ended March 31, 2024.
Transaction Price Allocated to Remaining Performance Obligations
Due to the ability of the client or the Company to cancel or terminate the contract within a given period of time (generally 10 to 30 days’ notice is required), the majority of the Company’s contracts have a term of less than one year. The Company does not disclose the value of unsatisfied performance obligations for contracts with an original maturity date of one year or less or time and materials contracts for which the Company has the right to invoice for services performed. Revenue related to unsatisfied performance obligations for remaining contracts as of March 31, 2024 was immaterial.
Disaggregation of Revenue
The following tables present revenue disaggregated by revenue source and pattern of revenue recognition (in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Three Months Ended March 31, |
| 2024 | | 2023 |
| Over Time | | Point In Time | | Total Revenues | | Over Time | | Point In Time | | Total Revenues |
Time and materials contracts | $ | 154.2 | | | $ | — | | | $ | 154.2 | | | $ | 175.5 | | | $ | — | | | $ | 175.5 | |
Fixed fee percent complete contracts | 14.9 | | | — | | | 14.9 | | | 14.8 | | | — | | | 14.8 | |
Fixed fee contracts | 40.7 | | | — | | | 40.7 | | | 36.3 | | | — | | | 36.3 | |
Reimbursable expenses | 3.6 | | | — | | | 3.6 | | | 2.5 | | | — | | | 2.5 | |
Total professional services fees | 213.4 | | | — | | | 213.4 | | | 229.1 | | | — | | | 229.1 | |
Other services revenue* | 1.2 | | | 0.3 | | | 1.5 | | | 1.4 | | | 0.3 | | | 1.7 | |
Total services | 214.6 | | | 0.3 | | | 214.9 | | | 230.5 | | | 0.3 | | | 230.8 | |
Software and hardware | — | | | 0.4 | | | 0.4 | | | — | | | 0.6 | | | 0.6 | |
Total revenues | $ | 214.6 | | | $ | 0.7 | | | $ | 215.3 | | | $ | 230.5 | | | $ | 0.9 | | | $ | 231.4 | |
*Other services revenue primarily consists of hosting fees, maintenance, training, internally developed SaaS revenue and partner referral fees.
The following table presents revenue disaggregated by geographic area, as determined by the billing address of customers (in millions):
| | | | | | | | | | | | | | | |
| Three Months Ended March 31, | | |
| 2024 | | 2023 | | | | |
United States | $ | 205.6 | | | $ | 223.5 | | | | | |
Other countries | 9.7 | | | 7.9 | | | | | |
Total revenues | $ | 215.3 | | | $ | 231.4 | | | | | |
5. Stock-Based Compensation
Stock-based compensation is accounted for in accordance with ASC Topic 718, Compensation – Stock Compensation. Under this guidance, the Company recognizes share-based compensation ratably using the straight-line attribution method over the requisite service period, which is generally three years. The fair value of restricted stock awards is based on the value of the Company’s common stock on the date of the grant.
The Company’s Third Amended and Restated 2012 Long Term Incentive Plan (as amended, the “Incentive Plan”) allows for the granting of various types of stock awards, not to exceed a total of 8.5 million shares, to eligible individuals. The Compensation Committee of the Board of Directors administers the Incentive Plan and determines the terms of all stock awards made under the Incentive Plan. As of March 31, 2024, there were 1.8 million shares of common stock available for issuance under the Incentive Plan.
Stock-based compensation cost recognized for the three months ended March 31, 2024 was $12.4 million, which included $1.0 million of expense for retirement savings plan contributions. The associated current and future income tax benefit recognized was $3.7 million for the three months ended March 31, 2024. Stock-based compensation cost recognized for the three months ended March 31, 2023 was $6.8 million, which included $1.1 million of expense for retirement savings plan contributions. The associated current and future income tax benefit recognized was $1.8 million for the three months ended March 31, 2023.
On February 23, 2024, Jeffrey S. Davis resigned his employee position as Executive Chairman of the Company, effective as of March 1, 2024. Mr. Davis is continuing as the non-executive Chairman of the Board of Directors. In connection with Mr. Davis’s resignation, the Board of Directors approved an amendment to certain existing restricted stock award agreements. Due to the resignation of Mr. Davis as Executive Chairman of the Company and the related restricted stock award amendment, the incremental share based compensation expense recorded during the three months ended March 31, 2024 was approximately $5.6 million.
Restricted Stock Awards (“RSAs”)
Restricted stock activity for the three months ended March 31, 2024 was as follows (shares in thousands):
| | | | | | | | | | | |
| RSAs (Shares) | | Weighted-Average Grant Date Fair Value |
Restricted stock awards outstanding at December 31, 2023 | 714 | | | $ | 70.80 | |
Awards granted | 195 | | | 69.04 | |
Awards vested | (194) | | | 73.93 | |
Awards forfeited | (17) | | | 68.42 | |
Restricted stock awards outstanding at March 31, 2024 | 698 | | | $ | 69.50 | |
As of March 31, 2024, there was $37.0 million of total unrecognized compensation cost related to non-vested RSAs with a weighted-average remaining life of two years.
Performance Stock Awards (“PSAs”)
In connection with the announcement of Thomas J. Hogan’s promotion to Chief Executive Officer, the Company granted a PSA of 10,842 shares to Mr. Hogan on July 25, 2023 under the Incentive Plan with terms determined at the discretion of the Compensation Committee of the Board of Directors. The actual number of shares subject to the PSA that will be eligible to vest is based on the achievement of a relative total shareholder return (“TSR”) target as compared to the TSR realized by each of the companies comprising the Nasdaq Composite Index over a three-year period. The grant date fair value of $80.90 per share was based on a Monte Carlo simulation model as of the date of the award. PSA related stock-based compensation cost recognized for the three months ended March 31, 2024 was $0.1 million. As of March 31, 2024, there was $0.7 million of total unrecognized compensation cost related to unvested PSAs, expected to be recognized over a period of three years.
6. Net Income per Share
The following table presents the calculation of basic and diluted net income per share (in thousands, except per share information):
| | | | | | | | | | | | | | | |
| Three Months Ended | | |
| March 31, | | |
| 2024 | | 2023 | | | | |
Net income, basic | $ | 11,555 | | | $ | 26,800 | | | | | |
Add back interest expense on convertible notes, net of tax | 534 | | | 560 | | | | | |
Net income, diluted | $ | 12,089 | | | $ | 27,360 | | | | | |
| | | | | | | |
Basic: | | | | | | | |
Weighted-average shares of common stock outstanding | 34,149 | | | 33,914 | | | | | |
Shares used in computing basic net income per share | 34,149 | | | 33,914 | | | | | |
Effect of dilutive securities: | | | | | | | |
Restricted stock and performance stock awards subject to vesting | 177 | | | 154 | | | | | |
Shares issuable for acquisition consideration (1) | 149 | | | 199 | | | | | |
Shares issuable for conversion of convertible senior notes | 2,430 | | | 2,430 | | | | | |
| | | | | | | |
Shares used in computing diluted net income per share | 36,905 | | | 36,697 | | | | | |
| | | | | | | |
Basic net income per share | $ | 0.34 | | | $ | 0.79 | | | | | |
Diluted net income per share | $ | 0.33 | | | $ | 0.75 | | | | | |
(1)For the three months ended March 31, 2024, this represents the shares held in escrow pursuant to: (i) the Asset Purchase Agreement with Zeon Solutions Incorporated and certain related entities (collectively, “Zeon”); (ii) the Purchase Agreement with Talos LLC, Talos Digital LLC, Talos Digital SAS and TCOMM SAS (collectively, “Talos”); (iii) the Stock Purchase Agreement with the shareholders of Izmul S.A. (“Overactive”); (iv) the Purchase Agreement with the shareholders of Ameex Technologies Corporation (“Ameex”); and (v) the Purchase Agreement with the shareholders of SMEDIX, Inc. (“SMEDIX”), as part of the consideration. For the three months ended March 31, 2023, this represents the shares held in escrow pursuant to: (i) the Asset Purchase Agreement with Zeon; (ii) the Asset Purchase Agreement with Catalyst Networks, Inc. (“Brainjocks”); (iii) the Stock Purchase Agreement with the shareholders of Productora de Software S.A.S. (“PSL”); (iv) the Purchase Agreement with Talos; (v) the Stock Purchase Agreement with the shareholders of Overactive; (vi) the Stock Purchase Agreement with the shareholders of Inflection Point Systems, Inc.; and (vii) the Purchase Agreement with the shareholders of Ameex, as part of the consideration.
The number of anti-dilutive securities not included in the calculation of diluted net income per share were as follows (in thousands):
| | | | | | | | | | | | | | | |
| Three Months Ended | | |
| March 31, | | |
| 2024 | | 2023 | | | | |
Restricted stock and performance stock awards subject to vesting | 109 | | | 276 | | | | | |
| | | | | | | |
Warrants related to the issuance of convertible senior notes | 2,431 | | | 2,431 | | | | | |
Total anti-dilutive securities | 2,540 | | | 2,707 | | | | | |
See Note 11, Long-term Debt for further information on the convertible senior notes and warrants related to the issuance of convertible notes.
The Company’s Board of Directors authorized the repurchase of up to $375.0 million of Company common stock through a stock repurchase program expiring December 31, 2024. The program could be suspended or discontinued at any time,
based on market, economic, or business conditions. The timing and amount of repurchase transactions will be determined by management based on its evaluation of market conditions, share price, and other factors. Since the program’s inception on August 11, 2008, the Company has repurchased approximately $291.1 million (16.5 million shares) of outstanding common stock through March 31, 2024.
7. Balance Sheet Components
| | | | | | | | | | | |
| March 31, 2024 (unaudited) | | December 31, 2023 |
Accounts receivable: | (in millions) |
Billed accounts receivable, net | $ | 97.6 | | | $ | 119.9 | |
Unbilled revenues, net | 74.2 | | | 59.1 | |
Total | $ | 171.8 | | | $ | 179.0 | |
| | | | | | | | | | | |
Other current assets: | | | |
Miscellaneous receivables | $ | 3.5 | | | $ | 3.1 | |
Contractual commitment asset | 3.4 | | | 3.0 | |
Income tax receivable | 3.2 | | | 2.7 | |
Other current assets | 3.4 | | | 3.6 | |
Total | $ | 13.5 | | | $ | 12.4 | |
| | | | | | | | | | | |
Property and equipment: | | | |
Computer hardware (useful life of 3 years) | $ | 25.5 | | | $ | 26.7 | |
Software (useful life of 1 to 7 years) | 9.1 | | | 9.2 | |
Furniture and fixtures (useful life of 5 years) | 4.3 | | | 4.5 | |
Leasehold improvements (useful life of 5 years) | 7.8 | | | 7.8 | |
Less: Accumulated depreciation | (36.3) | | | (36.2) | |
Total | $ | 10.4 | | | $ | 12.0 | |
| | | | | | | | | | | |
| | | |
Other non-current assets: | |
Non-current unbilled revenue | $ | 1.3 | | | $ | 2.2 | |
Company owned life insurance asset | 13.9 | | | 12.6 | |
Long term deposits | 1.9 | | | 1.8 | |
Credit facility deferred finance fees, net | 1.0 | | | 1.0 | |
Other non-current assets | 13.6 | | | 13.2 | |
Deferred income taxes | 22.2 | | | 21.6 | |
Total | $ | 53.9 | | | $ | 52.4 | |
| | | | | | | | | | | |
Other current liabilities: | |
Estimated fair value of contingent consideration liability (Note 9) | $ | 6.4 | | | $ | 4.5 | |
Accrued variable compensation | 13.1 | | | 15.9 | |
Current operating lease liabilities | 6.4 | | | 7.0 | |
Payroll related costs | 11.2 | | | 11.1 | |
Deferred revenues | 3.3 | | | 5.5 | |
Income tax payable | 4.7 | | | 1.5 | |
Other current liabilities | 5.8 | | | 4.8 | |
Accrued medical claims expense | 2.3 | | | 3.2 | |
Professional fees | 1.8 | | | 1.3 | |
Accrued IT expenses | 5.1 | | | 5.0 | |
Total | $ | 60.1 | | | $ | 59.8 | |
| | | |
| | | | | | | | | | | |
| March 31, 2024 (unaudited) | | December 31, 2023 |
Other non-current liabilities: | (in millions) |
Deferred income taxes | $ | 5.4 | | | $ | 5.9 | |
Reserve for uncertain tax positions | 18.4 | | | 17.7 | |
Deferred compensation liability | 12.5 | | | 11.0 | |
Other non-current liabilities | 4.6 | | | 5.0 | |
Non-current software accrual | 1.7 | | | 2.6 | |
Total | $ | 42.6 | | | $ | 42.2 | |
8. Allowance for Credit Losses
In accordance with ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, the Company evaluates its allowance based on expected losses rather than incurred losses, which is known as the current expected credit loss model. The allowance is determined using the loss rate approach and is measured on a collective (pool) basis when similar risk characteristics exist. Where financial instruments do not share risk characteristics, they are evaluated on an individual basis. The allowance is based on relevant available information, from internal and external sources, relating to past events, current conditions, and reasonable and supportable forecasts.
Activity in the allowance for credit losses is summarized as follows (in millions):
| | | | | | | | | | | |
| Three Months Ended March 31, |
| 2024 | | 2023 |
| | | |
| | | |
Opening balance at January 1 | $ | 2.5 | | | $ | 5.8 | |
Charges to expense, net of recoveries | (0.1) | | | — | |
Other (1) | (0.5) | | | (1.2) | |
Balance at March 31 | $ | 1.9 | | | $ | 4.6 | |
(1) Other is primarily related to uncollected balances written off and currency translation adjustments.
9. Business Combinations
2024 Acquisition
On January 16, 2024, the Company acquired all of the outstanding capital stock of SMEDIX. SEMDIX is a healthcare software engineering firm headquartered in San Diego, California, with offshore operations located in Cluj-Napoca, Romania. The acquisition of SMEDIX continued to strengthen our healthcare industry digital capabilities, enhance our global delivery capacity, and expand further within Eastern Europe. SMEDIX added more than 175 professionals and strategic client relationships focused in the biomedical and healthcare industry. The Company’s total allocable purchase price consideration was $43.6 million, net of cash acquired. The Company incurred approximately $1.7 million in transaction costs, which were expensed when incurred. The amount of goodwill deductible for tax purposes is $33.6 million.
The acquisition date fair value of the consideration transferred for SMEDIX consisted of the following (in millions):
| | | | | | | | |
| SMEDIX | |
Cash, net of cash acquired | $ | 33.2 | | |
Company common stock issued at closing | 3.8 | | |
Contingent consideration (1) | 6.4 | | (2) |
Net working capital adjustment due to the seller(s) | 0.2 | | |
Total allocable purchase price consideration | $ | 43.6 | | |
(1)Represents the initial fair value estimate of additional revenue and earnings-based contingent consideration, which may be realized by the sellers 12 months after the closing date of the acquisition.
(2)The maximum cash payout that may be realized by the sellers in the SMEDIX acquisition is $14.4 million. As of March 31, 2024, the fair value of the contingent consideration was $6.4 million.
The Company has estimated the preliminary allocation of the total purchase price consideration between tangible assets, identified intangible assets, liabilities, and goodwill as follows (in millions):
| | | | | |
| SMEDIX |
Acquired tangible assets | $ | 4.9 | |
Identified intangible assets | 8.9 | |
Liabilities assumed | (3.1) | |
Goodwill | 32.9 | |
Total allocable purchase price consideration | $ | 43.6 | |
The following table presents details of the intangible assets acquired during the three months ended March 31, 2024.
| | | | | | | | | | | | | | | | | |
| Weighted Average Useful Life | | Estimated Useful Life | | SMEDIX |
Customer relationships | 6 years | | 6 years | | $ | 7.0 | |
Customer backlog | 1 year | | 1 year | | 1.7 | |
Non-compete agreements | 5 years | | 5 years | | 0.1 | |
Trade name | 1 year | | 1 year | | 0.1 | |
Total acquired intangible assets | | | | | $ | 8.9 | |
The above purchase price accounting estimates for SMEDIX are pending finalization of certain acquired tangible and intangible assets, contingent consideration valuation, and a net working capital settlement that is subject to final adjustment as the Company evaluates information during the measurement period.
Pro-forma Results of Operations
Pro-forma results of operations have not been presented for SMEDIX because the effect of the acquisition on the Company's condensed consolidated financial statements was not material.
10. Goodwill and Intangible Assets
Goodwill represents the excess purchase price over the fair value of net assets acquired, or net liabilities assumed, in a business combination. In accordance with ASC Topic 350, Intangibles – Goodwill and Other, the Company performs an annual impairment review in the fourth quarter and more frequently if events or changes in circumstances indicate that goodwill might be impaired. There was no indication that goodwill became impaired for the three months ended March 31, 2024.
Other intangible assets include customer relationships, non-compete arrangements, trade names, customer backlog, and developed software, which are being amortized over the assets’ estimated useful lives using the straight-line method. Estimated useful lives range from less than one year to ten years. Amortization of customer relationships, non-compete arrangements, trade names, customer backlog, and developed software is considered an operating expense and is included in “Amortization” in the accompanying Unaudited Condensed Consolidated Statements of Operations. The Company periodically reviews the estimated useful lives of its identifiable intangible assets, taking into consideration any events or circumstances that might result in a lack of recoverability or revised useful life. There was no indication that other intangible assets became impaired for the three months ended March 31, 2024.
Goodwill
The changes in the carrying amount of goodwill for the three months ended March 31, 2024 are as follows (in millions):
| | | | | |
Balance at December 31, 2023 | $ | 581.4 | |
Purchase price allocation for SMEDIX | 32.9 | |
Effect of foreign currency translation adjustments | (0.5) | |
Balance at March 31, 2024 | $ | 613.8 | |
Intangible Assets with Definite Lives
The following table presents a summary of the Company’s intangible assets that are subject to amortization (in millions):
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| March 31, 2024 (unaudited) | | December 31, 2023 |
| Gross Carrying Amounts | | Accumulated Amortization | | Net Carrying Amounts | | Gross Carrying Amounts | | Accumulated Amortization | | Net Carrying Amounts |
Customer relationships | $ | 122.9 | | | $ | (51.1) | | | $ | 71.8 | | | $ | 116.1 | | | $ | (47.3) | | | $ | 68.8 | |
Non-compete agreements | 1.2 | | | (0.6) | | | 0.6 | | | 1.1 | | | (0.6) | | | 0.5 | |
Customer backlog | 1.7 | | | (0.4) | | | 1.3 | | | — | | | — | | | — | |
Trade name | 0.9 | | | (0.8) | | | 0.1 | | | 0.8 | | | (0.8) | | | — | |
Developed software | 8.8 | | | (7.2) | | | 1.6 | | | 8.5 | | | (6.7) | | | 1.8 | |
Total | $ | 135.5 | | | $ | (60.1) | | | $ | 75.4 | | | $ | 126.5 | | | $ | (55.4) | | | $ | 71.1 | |
The estimated useful lives of identifiable intangible assets are as follows:
| | | | | |
Customer relationships | 5 - 10 years |
Non-compete agreements | 4 - 5 years |
Customer backlog | 1 year |
Trade name | 1 year |
Developed software | 1 - 7 years |
Estimated annual amortization expense for the next five years ended December 31 and thereafter is as follows (in millions):
| | | | | |
2024 remaining | $ | 13.9 | |
2025 | $ | 13.4 | |
2026 | $ | 10.9 | |
2027 | $ | 8.5 | |
2028 | $ | 7.4 | |
Thereafter | $ | 21.3 | |
11. Long-term Debt
Revolving Credit Facility
On March 29, 2023, the Company amended and restated its existing credit agreement by entering into a Second Amended and Restated Credit Agreement (the “2023 Credit Agreement”) with Wells Fargo Bank, National Association, as administrative agent and the other lenders parties thereto. The 2023 Credit Agreement provides for revolving credit borrowings up to a maximum principal amount of $300.0 million, subject to a commitment increase of $75.0 million. All outstanding
amounts owed under the 2023 Credit Agreement become due and payable no later than the final maturity date of March 29, 2028. As of March 31, 2024, there was no outstanding balance under the 2023 Credit Agreement. The Company incurred $0.8 million of additional deferred finance fees during the three months ended March 31, 2023.
The 2023 Credit Agreement also allows for the issuance of letters of credit in the aggregate amount of up to $10.0 million at any one time; outstanding letters of credit reduce the credit available for revolving credit borrowings. As of March 31, 2024, there were no outstanding letters of credit. Substantially all of the Company’s assets are pledged to secure the credit facility.
Borrowings under the 2023 Credit Agreement bear interest at the Company’s option of the prime rate (8.50% on March 31, 2024) plus a margin ranging from 0.00% to 1.00% or one month Secured Overnight Financing Rate (“SOFR”) (5.34% on March 31, 2024) plus a margin ranging from 1.00% to 2.00%. The Company incurs an annual commitment fee of 0.15% to 0.20% on the unused portion of the line of credit. The additional margin amount and annual commitment fee are dependent on the level of outstanding borrowings. As of March 31, 2024, the Company had $300.0 million of unused borrowing capacity.
The Company is required to comply with various financial covenants under the 2023 Credit Agreement. At March 31, 2024, the Company was in compliance with all covenants under the 2023 Credit Agreement.
Convertible Senior Notes due 2026
On November 9, 2021, the Company issued $380.0 million aggregate principal amount of 0.125% Convertible Senior Notes Due 2026 (the “2026 Notes”) in a private placement to qualified institutional buyers pursuant to an exemption from registration provided by Section 4(a)(2) and Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The 2026 Notes bear interest at a rate of 0.125% per year. Interest is payable in cash on May 15 and November 15 of each year, with the first payment made on May 15, 2022. The 2026 Notes mature on November 15, 2026 unless earlier converted, redeemed or repurchased in accordance with their terms prior to such date. The initial conversion rate is 5.2100 shares of the Company’s common stock per $1,000 principal amount of 2026 Notes, which is equivalent to an initial conversion price of approximately $191.94 per share of common stock. After consideration of the 2026 Notes Hedges and 2026 Notes Warrants (as defined and described below), the conversion rate is effectively hedged to a price of $295.29 per share of common stock. The conversion rate, and thus the conversion price, may be adjusted under certain circumstances as described in the indenture governing the 2026 Notes (the “2026 Indenture”). The Company may settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at the Company’s election, based on the applicable conversion rate(s). If a “make-whole fundamental change” (as defined in the 2026 Indenture) occurs, then the Company will in certain circumstances increase the conversion rate for a specified period of time. The Company’s intent is to settle the principal amount of the 2026 Notes in cash upon conversion.
Convertible Senior Notes due 2025
On August 14, 2020, the Company issued $230.0 million aggregate principal amount of 1.250% Convertible Senior Notes Due 2025 (the “2025 Notes”) in a private placement to qualified institutional purchasers pursuant to an exemption from registration provided by Section 4(a)(2) and Rule 144A under the Securities Act. The 2025 Notes bear interest at a rate of 1.250% per year. Interest is payable in cash on February 1 and August 1 of each year. The 2025 Notes mature on August 1, 2025 unless earlier converted, redeemed or repurchased in accordance with their terms prior to such date. The initial conversion rate is 19.3538 shares of the Company’s common stock per $1,000 principal amount of 2025 Notes, which is equivalent to an initial conversion price of approximately $51.67 per share of common stock. After consideration of the 2025 Notes Hedges and 2025 Notes Warrants (as defined and described below), the conversion rate is effectively hedged to a price of $81.05 per share of common stock. The conversion rate, and thus the conversion price, may be adjusted under certain circumstances as described in the indenture governing the 2025 Notes (the “2025 Indenture”). The Company may settle conversions by paying or delivering, as applicable, cash, shares of its common stock or a combination of cash and shares of its common stock, at the Company’s election, based on the applicable conversion rate(s). If a “make-whole fundamental change” (as defined in the 2025 Indenture) occurs, then the Company will in certain circumstances increase the conversion rate for a specified period of time. The Company’s intent is to settle the principal amount of the 2025 Notes in cash upon conversion.
Other Terms of the Notes
The 2025 Notes and 2026 Notes may be converted at the holder’s option prior to the close of business on the business day immediately preceding August 1, 2025 for the 2025 Notes and November 15, 2026 for the 2026 Notes, but only under the following circumstances:
•during any calendar quarter commencing after the calendar quarter ending on September 30, 2020 for the 2025 Notes and December 31, 2021 for the 2026 Notes, if the last reported sale price per share of the Company’s common stock exceeds 130% of the applicable conversion price for each of at least 20 trading days during the 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding calendar quarter;
•during the five consecutive business days immediately after any 10 consecutive trading day period (such 10 consecutive trading day period, the “measurement period”) in which the trading price per $1,000 principal amount of notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price per share of the Company’s common stock on such trading day and the applicable conversion rate on such trading day;
•upon the occurrence of certain corporate events or distributions on the Company’s common stock described in the 2025 Indenture and 2026 Indenture; and
•at any time from, and including, February 3, 2025 for 2025 Notes and May 15, 2026 for 2026 Notes, until the close of business on the second scheduled trading day immediately before the maturity date for the 2025 Notes and 2026 Notes.
The Company may not redeem the 2025 Notes and 2026 Notes at its option before maturity. If a “fundamental change” (as defined in the 2025 Indenture and 2026 Indenture) occurs, then, except as described in the 2025 Indenture and 2026 Indenture, noteholders may require the Company to repurchase their 2025 Notes and 2026 Notes at a cash repurchase price equal to the principal amount of the 2025 Notes and 2026 Notes to be repurchased, plus accrued and unpaid interest, if any.
As of March 31, 2024, none of the conditions permitting holders to convert their 2025 Notes and 2026 Notes had been satisfied and no shares of the Company’s common stock had been issued in connection with any conversions of the 2025 Notes and 2026 Notes during the three months ended March 31, 2024. Based on the closing price of the Company's common stock of $56.29 per share on March 31, 2024, the conversion value of the 2026 Notes was less than the principal amount of the 2026 Notes outstanding on a per note basis, and the conversion value of the 2025 Notes was greater than the principal amount of the 2025 Notes outstanding on a per note basis.
The 2025 Notes and 2026 Notes consisted of the following (in millions):
| | | | | | | | | | | | | | | |
| March 31, 2024 (unaudited) | | |
Long-term debt: | 2026 Notes | | 2025 Notes | | | | |
Principal | $ | 380.0 | | | $ | 23.3 | | | | | |
Less: Unamortized debt issuance costs | (5.6) | | | (0.2) | | | | | |
Net carrying amount | $ | 374.4 | | | $ | 23.1 | | | | | |
| | | | | | | | | | | | | | | |
| December 31, 2023 | | |
Long-term debt: | 2026 Notes | | 2025 Notes | | | | |
Principal | $ | 380.0 | | | $ | 23.3 | | | | | |
| | | | | | | |
Less: Unamortized debt issuance costs | (6.1) | | | (0.3) | | | | | |
Net carrying amount | $ | 373.9 | | | $ | 23.0 | | | | | |
Interest expense for the three months ended March 31, 2024 and 2023 related to the 2026 Notes and 2025 Notes consisted of the following (in millions):
2026 Notes
| | | | | | | | | | | | | | | |
| Three Months Ended | | |
| March 31, | | |
| 2024 | | 2023 | | | | |
Coupon interest | $ | 0.1 | | | $ | 0.1 | | | | | |
| | | | | | | |
Amortization of debt issuance costs | 0.6 | | | 0.6 | | | | | |
Total interest expense recognized | $ | 0.7 | | | $ | 0.7 | | | | | |
2025 Notes
| | | | | | | | | | | | | | | |
| Three Months Ended | | |
| March 31, | | |
| 2024 | | 2023 | | | | |
Coupon interest | $ | 0.1 | | | $ | 0.1 | | | | | |
| | | | | | | |
Amortization of debt issuance costs | — | | | — | | | | | |
Total interest expense recognized | $ | 0.1 | | | $ | 0.1 | | | | | |
Convertible Notes Hedges
In connection with the issuance of the 2026 Notes and 2025 Notes, the Company entered into privately negotiated convertible note hedge transactions (the “2026 Notes Hedges” and the “2025 Notes Hedges”), and together, the “Notes Hedges”) with certain of the initial purchasers or their respective affiliates and/or other financial institutions (the “Option Counterparties”). As of March 31, 2024, the 2026 Notes Hedges provide the Company with the option to acquire, on a net settlement basis, approximately 2.0 million shares of common stock at a strike price of $191.94, which is equal to the number of shares of common stock that notionally underlie the 2026 Notes and correspond to the conversion price of the 2026 Notes. As of March 31, 2024, the 2025 Notes Hedges provided the Company with the option to acquire, on a net settlement basis, approximately 0.5 million shares of common stock at a strike price of $51.67, which is equal to the number of shares of common stock that notionally underlie the 2025 Notes and correspond to the conversion price of the 2025 Notes. If the Company elects cash settlement and exercises the Notes Hedges, the aggregate amount of cash received from the Option Counterparties will cover the aggregate amount of cash that the Company would be required to pay to the holders of the Notes, less the principal amount thereof. The Notes Hedges do not meet the criteria for separate accounting as a derivative as they are indexed to the Company’s stock and are accounted for as freestanding financial instruments.
Convertible Notes Warrants
In connection with the issuance of the 2026 Notes and 2025 Notes, the Company also sold net-share-settled warrants (the “2026 Notes Warrants” and the “2025 Notes Warrants,” respectively, and together, the “Notes Warrants”) in privately negotiated transactions with the Option Counterparties. The strike price of the 2026 Notes Warrants and 2025 Notes Warrants was approximately $295.29 and $81.05 per share, respectively, and is subject to certain adjustments under the terms of their respective Notes Warrants. As a result of the 2026 Notes Warrants and 2025 Notes Warrants and related transactions, the Company is required to recognize incremental dilution of earnings per share to the extent the average share price for any fiscal quarter is over $295.29 for the 2026 Notes Warrants and $81.05 for the 2025 Notes Warrants. The 2026 Notes Warrants and the 2025 Notes Warrants expire over a period of 80 trading days commencing on February 15, 2027 and over a period of 100 trading days commencing on November 1, 2025, respectively, and may be settled in net shares of common stock or net cash at the Company’s election. As of March 31, 2024, 2.0 million warrant shares and 0.5 million warrant shares were outstanding for the 2026 Notes Warrants and 2025 Notes Warrants, respectively.
12. Income Taxes
The Company's effective tax rate was 30.0% for the three months ended March 31, 2024, which was higher than the U.S. statutory rate of 21.0% primarily due to state taxes, share-based compensation and Section 162(m) compensation limitations.
The Company’s effective tax rate was 26.6% for the three months ended March 31, 2023, which was higher than the U.S. statutory rate of 21.0% primarily due to state taxes and foreign operations.
13. Derivatives
In the normal course of business, the Company uses derivative financial instruments to manage foreign currency exchange rate risk. Currency exposure is monitored and managed by the Company as part of its risk management program which seeks to reduce the potentially adverse effects that market volatility could have on operating results. The Company’s derivative financial instruments consist of non-deliverable and deliverable foreign currency forward contracts. Derivative financial instruments are neither held nor issued by the Company for trading purposes.
Derivatives Not Designated as Hedging Instruments
Both the gain or loss on the derivatives not designated as hedging instruments and the offsetting loss or gain on the hedged item attributable to the hedged risk are recognized in current earnings. Realized gains or losses and changes in the estimated fair value of foreign currency forward contracts that have not been designated as hedges were a net loss of $0.2 million during the three months ended March 31, 2024. Realized gains or losses and changes in the estimated fair value of foreign currency forward contracts that have not been designated as hedges were a net gain of $0.4 million during the three months ended March 31, 2023. Gains and losses on these contracts are recorded in net other expense (income) and net interest expense in the Unaudited Condensed Consolidated Statements of Operations and are offset by losses and gains on the related hedged items.
The notional amounts of the Company’s derivative instruments outstanding were as follows (in millions):
| | | | | | | | | | | |
| March 31, 2024 (unaudited) | | December 31, 2023 |
Derivatives not designated as hedges | | | |
Foreign exchange contracts | $ | 28.2 | | | $ | 26.2 | |
Total derivatives not designated as hedges | $ | 28.2 | | | $ | 26.2 | |
14. Fair Value Measurements
The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions.
The fair value hierarchy consists of the following three levels:
•Level 1 – Inputs are quoted prices in active markets for identical assets or liabilities.
•Level 2 – Inputs are quoted prices for similar assets or liabilities in an active market, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable and market-corroborated inputs which are derived principally from or corroborated by observable market data.
•Level 3 – Inputs are derived from valuation techniques in which one or more significant inputs or value drivers are unobservable.
The carrying value of cash, cash equivalents and restricted cash, accounts receivable, accounts payable, current liabilities and the revolving line of credit approximate fair value because of the short maturity of these instruments.
All highly liquid investments with maturities at date of purchase of three months or less are considered to be cash equivalents. Based on their short-term nature, the carrying value of cash equivalents approximate their fair value. As of March 31, 2024 and December 31, 2023, $54.5 million and $45.3 million, respectively of the Company’s cash, cash equivalents and restricted cash balance related to Level 1 investments.
The Company has a deferred compensation plan, which is funded through Company owned life insurance (“COLI”) policies. The COLI asset is carried at fair value derived from quoted market prices of investments within the COLI policies, which are considered Level 2 inputs. The fair value of the COLI asset was $13.9 million and $12.6 million as of March 31, 2024 and December 31, 2023, respectively.
The Company estimates the fair value of each foreign exchange forward contract by using the present value of expected cash flows. The estimate takes into account the difference between the current market forward price and contracted forward price for each foreign exchange contract and applies the difference in the rates to each outstanding contract. Valuations for all derivatives fall within Level 2 of the GAAP valuation hierarchy. The fair values of the Company’s derivative instruments outstanding as of March 31, 2024 and December 31, 2023 were immaterial.
The Company has contingent consideration liabilities related to acquisitions which are measured on a recurring basis and recorded at fair value, determined using the discounted cash flow method. The inputs used to calculate the fair value of the contingent consideration liabilities are considered to be Level 3 inputs due to the lack of relevant market activity and significant management judgment. An increase in future cash flows may result in a higher estimated fair value while a decrease in future cash flows may result in a lower estimated fair value of the contingent consideration liabilities. Remeasurements to fair value are recorded in adjustment to fair value of contingent consideration in the Unaudited Condensed Consolidated Statements of Operations. Refer to Note 7, Balance Sheet Components, for the estimated fair value of the contingent consideration liabilities as of March 31, 2024 and December 31, 2023.
The fair value of the Notes is measured using quoted price inputs. The Notes are not actively traded, and thus the price inputs represent a Level 2 measurement. As the quoted price inputs are highly variable from day to day, the fair value estimates could significantly increase or decrease.
The Notes are carried at their principal amount less unamortized issuance costs, and are not carried at fair value at each period end. The approximate fair value of the 2026 Notes as of March 31, 2024 and December 31, 2023 was $328.9 million and $316.1 million, respectively. The approximate fair value of the 2025 Notes as of March 31, 2024 and December 31, 2023 was $28.3 million and $32.4 million, respectively. The fair values were estimated on the basis of inputs that are observable in the market and are considered Level 2 fair value measurements.
15. Leases
The Company leases office space under various operating lease agreements, which have remaining lease terms of less than one year to seven years. Operating leases are included in operating lease right-of-use assets, other current liabilities, and operating lease liabilities on the consolidated balance sheet. Operating lease expense for the three months ended March 31, 2024 and 2023 were $3.0 million and $3.3 million, respectively.
Supplemental balance sheet information related to leases was as follows (in millions):
| | | | | | | | | | | |
| March 31, 2024 (unaudited) | | December 31, 2023 |
Other current liabilities | $ | 6.4 | | | $ | 7.0 | |
Operating lease liabilities | 17.9 | | | 16.4 | |
Total | $ | 24.3 | | | $ | 23.4 | |
Future minimum lease payments as of March 31, 2024 were as follows (in millions):
| | | | | |
| March 31, 2024 (unaudited) |
2024 remaining | $ | 5.4 | |
2025 | 6.9 | |
2026 | 4.8 | |
2027 | 4.5 | |
2028 | 3.4 | |
Thereafter | 2.0 | |
Total future lease payments | 27.0 | |
Less implied interest | (2.7) | |
Total | $ | 24.3 | |
16. Commitments and Contingencies
From time to time the Company is involved in legal proceedings, claims and litigation related to employee claims, contractual disputes and taxes in the ordinary course of business. Although the Company cannot predict the outcome of such matters, currently the Company has no reason to believe the disposition of any current matter could reasonably be expected to have a material adverse impact on the Company’s financial position, results of operations or the ability to carry on any of its business activities.
17. Subsequent Event
On May 5, 2024, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Plano HoldCo, Inc., a Delaware corporation (“Parent”), and Plano BidCo, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”). Parent and Merger Sub are affiliates of EQT Asia. Pursuant to the Merger Agreement, Merger Sub will be merged with and into the Company, with the Company surviving as a wholly owned subsidiary of Parent (the “Merger” and, collectively with the other transactions contemplated by the Merger Agreement, the “Transactions”). Under the terms of the Merger Agreement, the Company’s stockholders will receive $76.00 in cash per share of Company common stock outstanding as of the closing of the Merger.
Consummation of the Merger is subject to various conditions, including, among others, customary conditions relating to the adoption of the Merger Agreement by the holders of a majority of the Company’s outstanding common stock, the expiration or termination of any applicable waiting periods under the Hart-Scott-Rodino Act, conclusion of any review or investigation of the Transactions by the Committee on Foreign Investment in the United States, the receipt of certain foreign regulatory approvals and other customary conditions for a transaction of this type, such as the absence of any legal restraint prohibiting the consummation of the Transactions and the absence of any Company Material Adverse Effect (as defined in the Merger Agreement). Consummation of the Merger is not subject to any financing condition, and is expected to occur by the end of 2024.
The Company expects to incur significant costs, expenses and fees for professional services and other transaction costs in connection with the Merger Agreement. If the Merger Agreement is terminated under specified circumstances, Parent may be required to pay a termination fee of $162.6 million to the Company.
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Statements made in this Form 10-Q, including without limitation this Management’s Discussion and Analysis of Financial Condition and Results of Operations, other than statements of historical information, are forward looking statements within the meaning of Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements may sometimes be identified by such words as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” or “continue” or the negative of those words and other comparable words. We believe that it is important to communicate our future expectations to investors. However, these forward-looking statements involve many risks and uncertainties. Our actual results could differ materially from those indicated in such forward-looking statements as a result of certain factors, including but not limited to, those set forth under “Risk Factors” in our Annual Report on Form 10-K previously filed with the SEC and elsewhere in this Form 10-Q. We are under no duty to update any of the forward-looking statements after the date of this Form 10-Q to conform these statements to actual results. For additional information, see the “Special Note Regarding Forward-Looking Statements” contained in this Form 10-Q.
Overview
Perficient is a global digital consultancy transforming how the world’s biggest brands connect with customers and grow their businesses. We help clients, primarily focused in North America, gain competitive advantage by using digital technology to: make their businesses more responsive to market opportunities; strengthen relationships with customers, suppliers, and partners; improve productivity; and reduce information technology costs. With unparalleled strategy, creative and technology capabilities, across industries, our end-to-end digital consulting services help our clients drive faster speed-to-market capabilities and stronger, more compelling experiences for consumers. We go to market with six primary service categories – strategy and transformation, data and intelligence, platforms and technology, customer experience and digital marketing, innovation and product development, and optimized global delivery. Within each service category, and collectively, we deliver a deep and broad portfolio of solutions that enable our clients to operate a real-time enterprise that dynamically adapts business processes and the systems that support them to meet the changing demands of a global and competitive marketplace.
Services Revenues
Services revenues are derived from professional services that include developing, implementing, integrating, automating and extending business processes, technology infrastructure, and software applications. Professional services revenues are recognized over time as services are rendered. Most of our projects are performed on a time and materials basis, while a portion of our revenues is derived from projects performed on a fixed fee or fixed fee percent complete basis. For time and material projects, revenues are recognized and billed by multiplying the number of hours our professionals expend in the performance of the project by the hourly rates. For fixed fee contracts, revenues are recognized and billed by multiplying the established fixed rate per time period by the number of time periods elapsed. For fixed fee percent complete projects, revenues are generally recognized using an input method based on the ratio of hours expended to total estimated hours. Fixed fee percent complete engagements represented 7% of our services revenues for the three months ended March 31, 2024, and 6% for the three months ended March 31, 2023, respectively. On most projects, we are reimbursed for out-of-pocket expenses including travel and other project-related expenses. These reimbursements are included as a component of the transaction price of the respective professional services contract. The aggregate amount of reimbursed expenses will fluctuate depending on the location of our clients, the total number of our projects that require travel, and whether our arrangements with our clients provide for the reimbursement of such expenses. In conjunction with services provided, we occasionally receive referral fees under partner programs. These referral fees are recognized at a point in time when earned and recorded within services revenues.
Software and Hardware Revenues
Software and hardware revenues are derived from sales of third-party software and hardware resales, in which we are considered the agent, and sales of internally developed software, in which we are considered the principal. Revenues from sales of third-party software and hardware are recorded on a net basis, while revenues from internally developed software sales are recorded on a gross basis. Software and hardware revenues are expected to fluctuate depending on our clients’ demand for these products.
There are no significant cancellation or termination-type provisions for our software and hardware sales. Contracts for our professional services provide for a general right, to the client or us, to cancel or terminate the contract within a given period of time (generally 10 to 30 days’ notice is required). The client is responsible for any time and expenses incurred up to the date of cancellation or termination of the contract.
Cost of Revenues
Cost of revenues consists of cost of services, primarily related to cash and non-cash compensation and benefits (including bonuses and non-cash compensation related to equity awards), costs associated with subcontractors, reimbursable expenses and other project-related expenses. Cost of revenues does not include depreciation of assets used in the production of revenues which are primarily personal computers, servers, and other information technology related equipment. In accordance with Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers, sales of third-party software and hardware are presented on a net basis, and as such, third-party software and hardware costs are not presented within cost of revenues.
Our cost of services as a percentage of services revenues is affected by the utilization rates of our professionals (defined as the percentage of our professionals’ time billed to clients divided by the total available hours in the respective period), the salaries we pay our professionals, and the average billing rate we receive from our clients. If a project ends earlier than scheduled, we retain professionals in advance of receiving project assignments, or demand for our services declines, our utilization rate will decline and adversely affect our cost of services as a percentage of services revenues.
Selling, General, and Administrative Expenses
Selling, general and administrative (“SG&A”) expenses are primarily composed of sales-related costs, general and administrative salaries, stock compensation expense, office costs, recruiting expense, variable compensation costs, marketing costs and other miscellaneous expenses.
Plans for Growth and Acquisitions
Our goal is to continue to build one of the leading information technology consulting firms by expanding our relationships with existing and new clients and through the continuation of our disciplined acquisition strategy. Our future growth plan includes expanding our business with a primary focus on customers in the United States, both organically and through acquisitions. We also intend to further leverage our existing offshore and nearshore capabilities to support our future growth and provide our clients flexible options for project delivery.
When analyzing revenue growth by base business compared to acquired companies in the Results of Operations section below, revenue attributable to base business includes revenue from an acquired company that has been owned for a full four quarters after the date of acquisition.
Results of Operations
Three months ended March 31, 2024 compared to three months ended March 31, 2023
Revenues. Total revenues decreased 7.0% to $215.3 million for the three months ended March 31, 2024 from $231.4 million for the three months ended March 31, 2023.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| Financial Results (in millions) | | Explanation for Increases (Decreases) Over Prior Year Period (in millions) |
| Three Months Ended March 31, | | Total Decrease Over Prior Year Period | | Increase Attributable to Revenue Delivered by Resources of Acquired Companies | | Decrease Attributable to Revenue Delivered by Base Business Resources |
| 2024 | | 2023 | |
Services revenues | $ | 214.9 | | | $ | 230.8 | | | $ | (15.9) | | | $ | 3.1 | | | $ | (19.0) | |
Software and hardware revenues | 0.4 | | | 0.6 | | | (0.2) | | | — | | | (0.2) | |
Total revenues | $ | 215.3 | | | $ | 231.4 | | | $ | (16.1) | | | $ | 3.1 | | | $ | (19.2) | |
Services revenues decreased 6.9% to $214.9 million for the three months ended March 31, 2024 from $230.8 million for the three months ended March 31, 2023. The decrease in services revenues is primarily attributable to services revenues delivered by base business resources, which decreased $19.0 million, partially offset by an increase of $3.1 million in services
revenues delivered by resources of acquired companies. Services revenues delivered by base business resources decreased primarily due to reduced demand and mix shift to offshore.
Software and hardware revenues decreased to $0.4 million for the three months ended March 31, 2024 from $0.6 million for the three months ended March 31, 2023.
Cost of Revenues (exclusive of depreciation and amortization, discussed separately below). Cost of revenues decreased 1.5% to $142.1 million for the three months ended March 31, 2024 from $144.2 million for the three months ended March 31, 2023. Services costs as a percentage of services revenues increased to 66.1% for the three months ended March 31, 2024 from 62.5% for the three months ended March 31, 2023, primarily due to higher employee salaries and benefits as a percentage of services revenues.
Selling, General and Administrative. SG&A expenses increased to $49.2 million for the three months ended March 31, 2024 from $43.9 million for the three months ended March 31, 2023. SG&A expenses as a percentage of revenues were 22.8% and 19.0% for the three months ended March 31, 2024 and March 31, 2023, respectively. The increase in SG&A expenses was primarily due to a $5.6 million increase in stock compensation expense resulting from Jeffrey S. Davis’s resignation as Executive Chairman of the Company and certain amendments to his outstanding award agreements in connection with his resignation.
Depreciation. Depreciation expense decreased 12.8% to $2.0 million for the three months ended March 31, 2024 from $2.3 million for the three months ended March 31, 2023. Depreciation expense as a percentage of revenues was 0.9% and 1.0% for the three months ended March 31, 2024 and March 31, 2023, respectively.
Amortization. Amortization expense decreased 16.0% to $4.9 million for the three months ended March 31, 2024 from $5.8 million for the three months ended March 31, 2023. Amortization expense as a percentage of revenues was 2.3% for the three months ended March 31, 2024 and 2.5% for the three months ended March 31, 2023. Amortization expense decreased primarily due to certain intangibles becoming fully amortized.
Acquisition Costs. Acquisition-related costs increased to $1.4 million for the three months ended March 31, 2024 from $0.1 million for the three months ended March 31, 2023. Costs were incurred for legal, accounting, tax, investment bank and advisor fees, and valuation services performed by third parties in connection with merger and acquisition-related activities. Acquisition costs increased primarily due to the acquisition of SMEDIX, Inc. (“SMEDIX”) that closed in January 2024.
Adjustment to Fair Value of Contingent Consideration. An immaterial adjustment was recorded during the three months ended March 31, 2024 which represents accretion for the SMEDIX revenue and earnings-based contingent consideration liabilities. An adjustment of $2.0 million was recorded to decrease the liability during the three months ended March 31, 2023 which represents the net fair market value adjustment to Inflection Point Systems, Inc. (“Inflection Point”) revenue and earnings-based contingent consideration liabilities, net of accretion for Inflection Point and Ameex Technologies Corporation (“Ameex”).
Net Interest (Income) Expense. Net interest income was $0.8 million for the three months ended March 31, 2024. Net interest expense was $0.5 million for the three months ended March 31, 2023. The decrease in net interest expense was primarily due to a $1.3 million increase in interest income resulting from higher average cash balances and higher rates.
Provision for Income Taxes. We provide for federal, state and foreign income taxes at the applicable statutory rates adjusted for non-deductible expenses. Our effective tax rate of 30.0% for the three months ended March 31, 2024 is higher than our effective tax rate of 26.6% for the three months ended March 31, 2023. The increase in effective tax rate was primarily due to the above described increase in shared-based compensation compared to the prior year quarter.
Liquidity and Capital Resources
Selected measures of liquidity and capital resources are as follows (in millions):
| | | | | | | | | | | |
| March 31, 2024 | | December 31, 2023 |
Cash, cash equivalents and restricted cash (1) | $ | 118.2 | | | $ | 128.9 | |
Working capital (including cash, cash equivalents and restricted cash) (2) | $ | 235.3 | | | $ | 247.5 | |
Amounts available under credit facility | $ | 300.0 | | | $ | 300.0 | |
(1) The balance at March 31, 2024 includes $23.6 million held by certain foreign subsidiaries which is not available to fund domestic operations unless deemed repatriated. We currently do not plan or foresee a need to repatriate such funds. The balance also includes $1.8 million in cash held by certain other foreign subsidiaries which is available to fund domestic operations. The balance at December 31, 2023 includes $20.6 million held by certain foreign subsidiaries which is not available to fund domestic operations unless deemed repatriated and includes $1.8 million in cash held by certain other foreign subsidiaries which is available to fund domestic operations. The Company’s restricted cash balance as of March 31, 2024 and December 31, 2023 was $0.2 million and $0.2 million, respectively.
(2) Working capital is total current assets less total current liabilities.
Net Cash Provided by Operating Activities
Net cash provided by operating activities for the three months ended March 31, 2024 was $32.0 million compared to net cash provided by operating activities of $41.3 million for the three months ended March 31, 2023. For the three months ended March 31, 2024, the primary components of operating cash flows were net income of $11.6 million, non-cash charges of $19.0 million and net operating asset reductions of $1.4 million. For the three months ended March 31, 2023, the primary components of operating cash flows were net income of $26.8 million, non-cash charges of $11.5 million and net operating asset reductions of $3.0 million.
Net Cash Used in Investing Activities
During the three months ended March 31, 2024, we used $0.7 million to purchase property and equipment and to develop software and $33.2 million for the acquisition of SMEDIX. During the three months ended March 31, 2023, we used $1.3 million to purchase property and equipment and to develop software.
Net Cash Used in Financing Activities
During the three months ended March 31, 2024, we used $4.3 million to remit taxes withheld as part of a net share settlement of restricted stock vesting. We also used $4.5 million to settle contingent consideration for the purchase of Inflection Point and Ameex and received proceeds from sales of stock through the Employee Stock Purchase Plan of $0.2 million. During the three months ended March 31, 2023, we used $2.4 million to repurchase shares of our common stock through the stock repurchase program and $5.1 million to remit taxes withheld as part of a net share settlement of restricted stock vesting. We also used $0.7 million for credit facility financing fees, used $21.5 million to settle contingent consideration for the purchase of Talos and Overactive and received proceeds from sales of stock through the Employee Stock Purchase Plan of $0.2 million.
Availability of Funds from Bank Line of Credit Facility
On March 29, 2023, the Company entered into the 2023 Credit Agreement with Wells Fargo Bank, National Association, as administrative agent and the other lenders parties thereto. The 2023 Credit Agreement provides for revolving credit borrowings up to a maximum principal amount of $300.0 million, subject to a commitment increase of $75.0 million. All outstanding amounts owed under the 2023 Credit Agreement become due and payable no later than the final maturity date of March 29, 2028. As of March 31, 2024, there was no outstanding balance under the 2023 Credit Agreement. The Company incurred $0.8 million of additional deferred finance fees during the three months ended March 31, 2023.
The 2023 Credit Agreement also allows for the issuance of letters of credit in the aggregate amount of up to $10.0 million at any one time; outstanding letters of credit reduce the credit available for revolving credit borrowings. As of March 31, 2024, there were no outstanding letters of credit. Substantially all of the Company’s assets are pledged to secure the credit facility.
Borrowings under the 2023 Credit Agreement bear interest at the Company’s option of the prime rate (8.50% on March 31, 2024) plus a margin ranging from 0.00% to 1.00% or one month Secured Overnight Financing Rate (“SOFR”) (5.34% on March 31, 2024) plus a margin ranging from 1.00% to 2.00%. The Company incurs an annual commitment fee of 0.15% to 0.20% on the unused portion of the line of credit. The additional margin amount and annual commitment fee are dependent on the level of outstanding borrowings. As of March 31, 2024, the Company had $300.0 million of unused borrowing capacity.
At March 31, 2024, the Company was in compliance with all covenants under the 2023 Credit Agreement.
Stock Repurchase Program
The Company’s Board of Directors authorized the repurchase of up to $375.0 million of Company common stock through a stock repurchase program expiring December 31, 2024. The program could be suspended or discontinued at any time based on market, economic, or business conditions. The timing and amount of repurchase transactions will be determined by management based on its evaluation of market conditions, share price, and other factors. Since the program’s inception on August 11, 2008, the Company has repurchased approximately $291.1 million (16.5 million shares) of outstanding common stock through March 31, 2024.
From time to time, the Company establishes a written trading plan in accordance with Rule 10b5-1 of the Exchange Act, pursuant to which the Company makes a portion of its stock repurchases. Additional repurchases will be at times and in amounts as the Company deems appropriate and will be made through open market transactions in compliance with Rule 10b-18 of the Exchange Act, subject to market conditions, applicable legal requirements, and other factors.
Cash Requirements from Contractual Obligations
For the three months ended March 31, 2024, there were no material changes outside the ordinary course of business in lease obligations or contractual obligations. See Note 15, Leases, in the Notes to Interim Condensed Consolidated Financial Statements for further description of our contractual obligations.
As of March 31, 2024 (unaudited) and December 31, 2023, there were no balances outstanding under the 2023 Credit Agreement. Any balances outstanding under the 2023 Credit Agreement would be classified as “Long-term debt” within the Condensed Consolidated Balance Sheet and become due and payable no later than the final maturity date of March 29, 2028. As of March 31, 2024, there were $397.4 million of outstanding 2026 Notes and 2025 Notes, net of unamortized issuance costs, compared to $396.9 million as of December 31, 2023. The amounts are classified as “Long-term debt” within the Condensed Consolidated Balance Sheets as of March 31, 2024 (unaudited) and December 31, 2023. The 2026 Notes will become due and payable no later than the final maturity date of November 15, 2026. The 2025 Notes will become due and payable no later than the final maturity date of August 1, 2025.
Conclusion
Of the total cash, cash equivalents and restricted cash reported on the Condensed Consolidated Balance Sheet as of March 31, 2024 (unaudited) of $118.2 million, $23.6 million was held by certain foreign subsidiaries and is considered to be indefinitely reinvested in those operations. The Company is able to fund its liquidity needs outside of these subsidiaries, primarily through cash flows generated by domestic operations and our credit facility. Therefore, the Company has no current plans to repatriate cash from these foreign subsidiaries in the foreseeable future. As of March 31, 2024, $1.8 million of the total cash, cash equivalents and restricted cash was held by the Company’s Chinese subsidiary, the earnings of which are not considered to be permanently reinvested and may be repatriated from time to time.
We believe that the currently available funds, access to capital from our credit facility, and cash flows generated from operations will be sufficient to meet our working capital requirements and other capital needs for the next 12 months.
Critical Accounting Policies
Our accounting policies are fully described in Note 2, Summary of Significant Accounting Policies, to our Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2023. We believe our most critical accounting policies include revenue recognition, purchase accounting and related fair value measurements, convertible debt, and income taxes.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
We are exposed to market risks related to changes in foreign currency exchange rates and interest rates. We believe our exposure to market risks is immaterial.
Exchange Rate Sensitivity
We are exposed to market risks associated with changes in foreign currency exchange rates because we generate a portion of our revenues and incur a portion of our expenses in currencies other than the U.S. dollar. As of March 31, 2024, we were exposed to changes in exchange rates between the U.S. dollar and twelve other currencies. We hedge material foreign
currency exchange rate exposures when feasible using forward contracts. These instruments are subject to fluctuations in foreign currency exchange rates and credit risk. Credit risk is managed through careful selection and ongoing evaluation of the financial institutions utilized as counterparties. Refer to Note 13, Derivatives, in the Notes to Interim Unaudited Condensed Consolidated Financial Statements for further discussion.
Interest Rate Sensitivity
As of March 31, 2024, there was no outstanding balance and $300.0 million of available borrowing capacity under our credit facility. To the extent we have outstanding borrowings under the credit facility, our interest expense will fluctuate as the interest rate for the line of credit floats based, at our option, on the prime rate plus a margin or the one-month SOFR rate plus a margin.
During the third quarter of 2020 and the fourth quarter of 2021, we issued the 2025 Notes and the 2026 Notes, respectively, which have a fixed interest rate of 1.250% and 0.125%, respectively. The fair value of the Notes may increase or decrease for various reasons, including fluctuations in the market price of our common stock, fluctuations in market interest rates and fluctuations in general economic conditions. Based upon the quoted market price as of March 31, 2024, the fair value of the 2025 Notes and 2026 Notes was approximately $28.3 million and $328.9 million, respectively.
We had unrestricted cash and cash equivalents totaling $118.0 million at March 31, 2024 and $128.7 million at December 31, 2023. The unrestricted cash and cash equivalents are primarily held for working capital purposes and acquisitions. We do not enter into investments for trading or speculative purposes.
Item 4. Controls and Procedures
The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company’s reports under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to management, including the principal executive officer and principal financial officer of the Company, as appropriate, to allow timely decisions regarding required disclosure. The Company’s management, with the participation of the Company’s principal executive officer and principal financial officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures as of the end of the period covered by this Form 10-Q. Based on that evaluation, the Company’s principal executive and principal financial officers have determined that the Company’s disclosure controls and procedures were effective.
There were no significant changes in the Company’s internal control over financial reporting as defined in Exchange Act Rule 13a-15(f) during the three months ended March 31, 2024, that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1A. Risk Factors
In evaluating all forward-looking statements, you should specifically consider various risk factors that may cause actual results to vary from those contained in the forward-looking statements. Our risk factors are described in our Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on February 27, 2024 and available at www.sec.gov.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Unregistered Sales of Securities
On January 16, 2024, the Company acquired all of the outstanding stock of SMEDIX. The consideration paid in this transaction included 68,441 unregistered shares of the Company’s common stock with an aggregate value of approximately $4.4 million based on the average closing sales price for the 15 consecutive trading days ending on the date immediately before the acquisition's closing date. We relied on Section 4(a)(2) of the Securities Act, as the basis for exemption from registration for each of these issuances. These shares were issued in privately negotiated transactions and not pursuant to a public solicitation.
Issuer Purchases of Equity Securities
The Company’s Board of Directors authorized the repurchase of up to $375.0 million of shares of Company common stock through a stock repurchase program expiring December 31, 2024. The Company originally announced the repurchase program on March 27, 2008 and announced its expansion to its current authorization on October 27, 2022. The program could be suspended or discontinued at any time based on market, economic, or business conditions. The Company has no other stock repurchase programs outstanding, nor did any stock repurchase programs expire during the three months ended March 31, 2024.
From the program’s inception on August 11, 2008 through March 31, 2024, we have repurchased approximately $291.1 million (16.5 million shares) of our outstanding common stock. The Company did not repurchase any shares through the stock repurchase program during the three months ended March 31, 2024.
The Company intends for the stock repurchase program and the repurchases made pursuant to the program to reduce the dilutive effect of shares issued by the Company both to acquisition targets as part of its acquisition program and to key employees and executives as a principal component of the Company’s compensation practices. The Company’s use of shares for these purposes is critical because it allows for the Company to align the interests of our executives, acquisition targets and other employees with those of our stockholders and helps to retain key employees. The timing and amount of repurchase transactions will be determined by management based on its evaluation of market conditions, share price, and other factors.
The Company’s officers and directors are required to comply with the Company’s securities trading policy at all times, including during a repurchase program. The insider trading policy, among other things, prohibits trading in the Company’s securities when in possession of material non-public information and restricts the ability of directors and certain officers from transacting in the Company’s securities during specific blackout periods, subject to certain limited exceptions, including transactions pursuant to a Rule 10b5-1 trading arrangement that complies with the conditions of Exchange Act Rule 10b5-1.
Item 5. Other Information
Officer and Director Rule 10b5-1 Trading Arrangements
There were no Rule 10b5-1 trading arrangements adopted, materially modified, or terminated by our officers and directors during the first quarter of 2024.
Company Rule 10b5-1 Trading Arrangements
The Company did not adopt, materially modify, or terminate any Rule 10b5-1 trading arrangements during the first quarter of 2024.
Item 6. Exhibits
See Exhibits Index.
EXHIBITS INDEX | | | | | |
Exhibit Number | Description |
3.1 | |
3.2 | |
4.1 | |
4.2 | |
4.3 | |
4.4 | |
4.5 | |
10.1†* | |
| Certification by the Chief Executive Officer of Perficient, Inc. as required by Section 302 of the Sarbanes-Oxley Act of 2002 |
| Certification by the Chief Financial Officer of Perficient, Inc. as required by Section 302 of the Sarbanes-Oxley Act of 2002 |
| Certification by the Chief Executive Officer and Chief Financial Officer of Perficient, Inc. pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
101* | The following financial information from Perficient, Inc.’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024 formatted in iXBRL (inline eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets as of March 31, 2024 (Unaudited) and December 31, 2023, (ii) Unaudited Condensed Consolidated Statements of Operations for the three months ended March 31, 2024 and 2023, (iii) Unaudited Condensed Consolidated Statements of Comprehensive Income for the three months ended March 31, 2024 and 2023, (iv) Unaudited Condensed Consolidated Statements of Shareholders’ Equity for the three months ended March 31, 2024 and 2023, (v) Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2024 and 2023, and (vi) the Notes to Interim Unaudited Condensed Consolidated Financial Statements |
104 | Cover Page Interactive Data File (formatted as iXBRL and contained in Exhibit 101) |
| |
† | Identifies an Exhibit that consists of or includes a management contract or compensatory plan or arrangement. |
* | Filed herewith. |
** | Included but not to be considered “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | | | | | | | | | | |
| | PERFICIENT, INC. |
| | | |
Date: | May 6, 2024 | By: | /s/ Thomas J. Hogan |
| | Thomas J. Hogan |
| | Chief Executive Officer (Principal Executive Officer) |
| | | | | | | | | | | |
Date: | May 6, 2024 | By: | /s/ Paul E. Martin |
| | Paul E. Martin |
| | Chief Financial Officer (Principal Financial Officer) |